This April Gordian Biotechnology came out of stealth with $60 million in funding and a bold strategy for accelerating gene therapy to tackle aging. Gordian is dosing individual animals with many genetically labeled candidate therapies simultaneously, and then analyzing the distinctive impact of each treatment on single cells in the different target tissues. Gordian is one of a small but growing number of companies that are pursuing high-throughput in vivo animal testing strategies, including startups like Vevo Therapeutics and Manifold Bio, as well as established biotech companies like Ginkgo Bioworks.
UCSF congratulates co-founders of Vevo TX, Hani Goodarzi and Kevan Shokat, both research royalty at UCSF, for being featured in Nature Biotechnology.